Chianelli M, Todino V, Graziano F M, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E
Nuclear Medicine Unit, Department of Diagnostics, Regina Apostolorum Hospital, Albano, Rome, Italy.
Eur J Endocrinol. 2009 Mar;160(3):431-6. doi: 10.1530/EJE-08-0669. Epub 2008 Dec 12.
(a) To compare the efficacy of low-activity (2 GBq; 54 mCi) (131)I ablation using l-thyroxine withdrawal or rhTSH stimulation, and (b) to assess the influence of thyroid remnants volume on the ablation rate.
Patients underwent neck ultrasound, (131)I neck scintigraphy and radioiodine uptake. Post-therapy whole body scan (WBS) was acquired after 4-6 days. Ablation was assessed after 6-12 months by WBS, Tg and TgAb following l-thyroxine withdrawal.
Group A: preparation by L-T(4) withdrawal (37 days); 21 patients received (131)I (2.02+/-0.22 GBq; 54.6+/-5.9 mCi) and on the day of treatment, TSH, Tg, TgAb were measured; Group B: stimulation by rhTSH; 21 patients received (131)I (1.97+/-0.18 GBq; 53.2+/-4.9 mCi) 24 h after the second injection of rhTSH (0.9 mg) and TSH, Tg and TgAb were measured after 2 days.
At follow-up, 90.0% of patients from group A and 85.0% of patients from group B had Tg levels <1 ng/ml; no uptake was observed in 95.2% and in 90.5% of patients from group A or B respectively, with no statistical differences for both ablation criteria. Before (131)I treatment, small thyroid remnants (<1 ml) were detected by US in <25% of all patients.
The use of rhTSH for the preparation of low-risk patients to ablation therapy with low activities of (131)I (2 GBq; 54 mCi) is safe and effective and avoids hypothyroidism. The presence of thyroid remnants smaller than 1 ml at US evaluation had no effect on the ablation rate.
(a) 比较采用左旋甲状腺素撤药或重组人促甲状腺素(rhTSH)刺激进行低活度(2GBq;54mCi)(131)I消融的疗效,以及(b) 评估甲状腺残余体积对消融率的影响。
患者接受颈部超声、(131)I颈部闪烁扫描及放射性碘摄取检查。治疗后4 - 6天进行治疗后全身扫描(WBS)。在左旋甲状腺素撤药后6 - 12个月,通过WBS、Tg和TgAb评估消融情况。
A组:通过左旋甲状腺素撤药进行准备(37天);21例患者接受(131)I(2.02±0.22GBq;54.6±5.9mCi),并在治疗当天测量TSH、Tg、TgAb;B组:通过rhTSH刺激;21例患者在第二次注射rhTSH(0.9mg)24小时后接受(131)I(1.97±0.18GBq;53.2±4.9mCi),并在2天后测量TSH、Tg和TgAb。
随访时,A组90.0%的患者和B组85.0%的患者Tg水平<1ng/ml;A组和B组分别有95.2%和90.5%的患者未观察到摄取,两种消融标准均无统计学差异。在(131)I治疗前,超声检查发现<25%的所有患者存在小的甲状腺残余(<1ml)。
对于低风险患者,使用rhTSH准备低活度(2GBq;54mCi)(131)I消融治疗是安全有效的,且可避免甲状腺功能减退。超声评估时甲状腺残余小于1ml对消融率无影响。